Advanced gene transfer technologies and profound immunological insights have enabled
substantial increases in the efficacy of anticancer adoptive cellular therapy (ACT). In recent …

RNA-based therapy has been an expanding area of clinical research since the COVID-19
outbreak. Often, its comparison has been made to DNA-based gene therapy, such as adeno …

The application of immunotherapies such as chimeric antigen receptor (CAR) T therapy or bi-
specific T cell engager (BiTE) therapy to manage myeloid malignancies has proven more …

CAR T-cell products targeting lineage-specific cell-of-origin antigens, thereby eliminating
both tumor and healthy counterpart cells, are currently clinically approved therapeutics in B …

In this review article, we outline the current landscape of immune and cell therapy-based
approaches for patients with myelodysplastic syndromes (MDS). Given the well …

Hematopoiesis is a finely orchestrated process, whereby hematopoietic stem cells give rise
to all mature blood cells. Crucially, they maintain the ability to self-renew and/or differentiate …

Introduction Minimal residual disease (MRD) has been an important biomarker for relapse
prediction and treatment choice in patients with acute myeloid leukemia (AML). False …

Non‐viral vector chimeric antigen receptor (CAR)‐T cells have garnered increasing attention
due to their ability to efficiently eradicate cancer cells while mitigating undesirable side …

In cancer immunotherapy, the design and optimisation of bispecific antibodies hold great
promise. Bispecific T-cell engager (BiTE) antibodies targeting CD3 and CD117/c-kit have …

CAR T-cell products targeting lineage-specific cell-of-origin antigens, thereby eliminating
both tumor and healthy counterpart cells, are currently clinically approved therapeutics in B …